🚀Day 4 Upper GI oral abstracts summary results #ESMO26 🟣

1) HRS-4642 (KRAS G12D inhibitor) in combination with GnP ± adebrelimab as perioperative therapy in resectable or borderline resectable KRAS G12D-mutant pancreatic cancer, ORR 63% and 87%

2) INCB161734, a novel oral KRAS G12D inhibitor, + GnP or mFFX in advanced pancreatic cancer , ORR 62% and 75%

3) LEAP-012 long-term OS data, pembro lenva TACE vs TACE in HCC , no OS benefit

4) C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced HCC, manageable safety profile and ORR 44%

5) maintenance olaparib in DDR gene-mutated advanced BTC adter 1L platinum based ChT, median OS 29.6 mo, 2-yer OS rate 53.6%

6) Subcutaneous envafolimab plus GEMOX vs GEMOX in 1L of advanced BTC provided OS benefit

#cancer #oncology #GI #MedX @OncoAlert